Zutig 50mg

BDR Pharmaceuticals

Antibacterial

Description
Shipping Options
Customer Reviews

ZUTIG is an injectable antibiotic containing Tigecycline (50 mg/vial), a broad-spectrum glycylcycline used for complicated infections caused by multidrug-resistant (MDR) bacteria.

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Excipients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits protein synthesis by binding to the 30S ribosomal subunit).
Effective against:
- Gram-positive (MRSA, VRE*, Streptococcus spp.)
- Gram-negative (E. coli, Klebsiella, Acinetobacter baumannii)
- Anaerobes (Bacteroides fragilis)
- Atypical bacteria (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited efficacy against some Enterococcus faecium strains)*

Dosage & Administration

Standard Adult Dose:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg every 12 hours (infused over 30–60 minutes).

Dosage Adjustments:

Severe hepatic impairment (Child-Pugh C): 25 mg every 12 hours.
No renal dose adjustment needed (primarily liver metabolism).

Pediatric Use:

Not recommended for children <18 years (risk of tooth/bone abnormalities).

Indications (Approved Uses)

Complicated Skin & Soft Tissue Infections (cSSTI)
Complicated Intra-Abdominal Infections (cIAI)
Community-Acquired Bacterial Pneumonia (CABP)
Resistant bacterial infections (when other options fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store below 25°C, protect from light.
Reconstituted solution:
- Stable for 6 hours at room temperature or 24 hours if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Use as a last-resort antibiotic (due to mortality risks in certain infections). ✔ Monitor for superinfections (C. difficile, fungal infections). ✔ Avoid in pregnancy (Category D) – risk of fetal harm. ✔ Assess liver function before/during therapy.

Black Box Warning (FDA)

⚠ Increased mortality risk observed in clinical trials (especially in hospital-acquired pneumonia). ⚠ Use only when no alternative treatments are available.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver enzyme elevations.
- Severe allergic reactions.

Drug Interactions

Warfarin → Increased bleeding risk (monitor INR).
Oral contraceptives → Reduced efficacy (use backup contraception).
Proton pump inhibitors → May reduce absorption (if switching to oral therapy).

Conclusion

ZUTIG (Tigecycline) is reserved for MDR infections when standard antibiotics fail. Strict monitoring is required due to safety concerns.

ZUTIG is an injectable antibiotic containing Tigecycline (50 mg/vial), a broad-spectrum glycylcycline used for complicated infections caused by multidrug-resistant (MDR) bacteria.

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Excipients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits protein synthesis by binding to the 30S ribosomal subunit).
Effective against:
- Gram-positive (MRSA, VRE*, Streptococcus spp.)
- Gram-negative (E. coli, Klebsiella, Acinetobacter baumannii)
- Anaerobes (Bacteroides fragilis)
- Atypical bacteria (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited efficacy against some Enterococcus faecium strains)*

Dosage & Administration

Standard Adult Dose:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg every 12 hours (infused over 30–60 minutes).

Dosage Adjustments:

Severe hepatic impairment (Child-Pugh C): 25 mg every 12 hours.
No renal dose adjustment needed (primarily liver metabolism).

Pediatric Use:

Not recommended for children <18 years (risk of tooth/bone abnormalities).

Indications (Approved Uses)

Complicated Skin & Soft Tissue Infections (cSSTI)
Complicated Intra-Abdominal Infections (cIAI)
Community-Acquired Bacterial Pneumonia (CABP)
Resistant bacterial infections (when other options fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store below 25°C, protect from light.
Reconstituted solution:
- Stable for 6 hours at room temperature or 24 hours if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Use as a last-resort antibiotic (due to mortality risks in certain infections).
✔ Monitor for superinfections (C. difficile, fungal infections).
✔ Avoid in pregnancy (Category D) – risk of fetal harm.
✔ Assess liver function before/during therapy.

Black Box Warning (FDA)

⚠ Increased mortality risk observed in clinical trials (especially in hospital-acquired pneumonia).
⚠ Use only when no alternative treatments are available.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver enzyme elevations.
- Severe allergic reactions.

Drug Interactions

Warfarin → Increased bleeding risk (monitor INR).
Oral contraceptives → Reduced efficacy (use backup contraception).
Proton pump inhibitors → May reduce absorption (if switching to oral therapy).

Conclusion

ZUTIG (Tigecycline) is reserved for MDR infections when standard antibiotics fail. Strict monitoring is required due to safety concerns.

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

ZUTIG is an injectable antibiotic containing Tigecycline (50 mg/vial), a broad-spectrum glycylcycline used for complicated infections caused by multidrug-resistant (MDR) bacteria.

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Excipients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits protein synthesis by binding to the 30S ribosomal subunit).
Effective against:
- Gram-positive (MRSA, VRE*, Streptococcus spp.)
- Gram-negative (E. coli, Klebsiella, Acinetobacter baumannii)
- Anaerobes (Bacteroides fragilis)
- Atypical bacteria (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited efficacy against some Enterococcus faecium strains)*

Dosage & Administration

Standard Adult Dose:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg every 12 hours (infused over 30–60 minutes).

Dosage Adjustments:

Severe hepatic impairment (Child-Pugh C): 25 mg every 12 hours.
No renal dose adjustment needed (primarily liver metabolism).

Pediatric Use:

Not recommended for children <18 years (risk of tooth/bone abnormalities).

Indications (Approved Uses)

Complicated Skin & Soft Tissue Infections (cSSTI)
Complicated Intra-Abdominal Infections (cIAI)
Community-Acquired Bacterial Pneumonia (CABP)
Resistant bacterial infections (when other options fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store below 25°C, protect from light.
Reconstituted solution:
- Stable for 6 hours at room temperature or 24 hours if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Use as a last-resort antibiotic (due to mortality risks in certain infections).
✔ Monitor for superinfections (C. difficile, fungal infections).
✔ Avoid in pregnancy (Category D) – risk of fetal harm.
✔ Assess liver function before/during therapy.

Black Box Warning (FDA)

⚠ Increased mortality risk observed in clinical trials (especially in hospital-acquired pneumonia).
⚠ Use only when no alternative treatments are available.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver enzyme elevations.
- Severe allergic reactions.

Drug Interactions

Warfarin → Increased bleeding risk (monitor INR).
Oral contraceptives → Reduced efficacy (use backup contraception).
Proton pump inhibitors → May reduce absorption (if switching to oral therapy).

Conclusion

ZUTIG (Tigecycline) is reserved for MDR infections when standard antibiotics fail. Strict monitoring is required due to safety concerns.

Reviews

There are no reviews yet.

Be the first to review “Zutig 50mg”

Description
Reviews (0)

ZUTIG is an injectable antibiotic containing Tigecycline (50 mg/vial), a broad-spectrum glycylcycline used for complicated infections caused by multidrug-resistant (MDR) bacteria.

Composition

Active Ingredient: Tigecycline 50 mg (as lyophilized powder).
Excipients: Hydrochloric acid, sodium hydroxide, lactose monohydrate.

Mechanism of Action

Bacteriostatic (inhibits protein synthesis by binding to the 30S ribosomal subunit).
Effective against:
- Gram-positive (MRSA, VRE*, Streptococcus spp.)
- Gram-negative (E. coli, Klebsiella, Acinetobacter baumannii)
- Anaerobes (Bacteroides fragilis)
- Atypical bacteria (Mycoplasma, Legionella)
Not effective against: Pseudomonas aeruginosa, Proteus spp.

(Limited efficacy against some Enterococcus faecium strains)*

Dosage & Administration

Standard Adult Dose:

Loading dose: 100 mg IV (single dose).
Maintenance: 50 mg every 12 hours (infused over 30–60 minutes).

Dosage Adjustments:

Severe hepatic impairment (Child-Pugh C): 25 mg every 12 hours.
No renal dose adjustment needed (primarily liver metabolism).

Pediatric Use:

Not recommended for children <18 years (risk of tooth/bone abnormalities).

Indications (Approved Uses)

Complicated Skin & Soft Tissue Infections (cSSTI)
Complicated Intra-Abdominal Infections (cIAI)
Community-Acquired Bacterial Pneumonia (CABP)
Resistant bacterial infections (when other options fail).

(Not approved for diabetic foot infections or bacteremia due to higher mortality risk.)

Storage & Stability

Unreconstituted vials: Store below 25°C, protect from light.
Reconstituted solution:
- Stable for 6 hours at room temperature or 24 hours if refrigerated (2–8°C).
Do not freeze or shake vigorously.

Key Recommendations

✔ Use as a last-resort antibiotic (due to mortality risks in certain infections).
✔ Monitor for superinfections (C. difficile, fungal infections).
✔ Avoid in pregnancy (Category D) – risk of fetal harm.
✔ Assess liver function before/during therapy.

Black Box Warning (FDA)

⚠ Increased mortality risk observed in clinical trials (especially in hospital-acquired pneumonia).
⚠ Use only when no alternative treatments are available.

Side Effects

Common: Nausea, vomiting, diarrhea, headache.
Serious:
- Acute pancreatitis.
- Liver enzyme elevations.
- Severe allergic reactions.

Drug Interactions

Warfarin → Increased bleeding risk (monitor INR).
Oral contraceptives → Reduced efficacy (use backup contraception).
Proton pump inhibitors → May reduce absorption (if switching to oral therapy).

Conclusion

ZUTIG (Tigecycline) is reserved for MDR infections when standard antibiotics fail. Strict monitoring is required due to safety concerns.

Reviews

There are no reviews yet.

Be the first to review “Zutig 50mg”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.